PURPOSE: Sinusoidal obstruction syndrome (SOS) is a life-threatening early complication after hematopoietic stem cell transplantation (HSCT), and until now, examinations about the influence of genetic risk factors are extremely rare. The purpose of this study was to identify an association between heparanase (HPSE) single nucleotide polymorphisms (SNPs) and SOS in children undergoing allogeneic HSCT. METHODS: We retrospectively analyzed the distribution of the both HPSE SNPs rs4693608 and rs4364254 and the occurrence of SOS after allogeneic HSCT in 160 children with malignant and non-malignant diseases. RESULTS: Patients with HPSE genotypes GG or AG of rs4693608 (G>A) had a significantly reduced incidence of SOS on day 100 after HSCT compared to patients with genotype AA (4.7 vs. 14.3 %, P = 0.038). In addition, incidence of SOS in patients with genotype CC or CT of rs4364254 (C>T) was significantly decreased in comparison with patients with genotype TT (2.3 vs. 14.7 %, P = 0.004). Interestingly, no patient with genotype CC developed SOS. Because both SNPs co-occur in vivo, we generated subsets: AA-TT, GG-CC, and a group with remaining SNP combinations. We found significant differences between all three patient groups (P = 0.035). Patients with AA-TT showed the highest incidence of SOS (16.7 %), while SOS did not appear in patients with GG-CC (0 %) and residual combinations were numerically in-between (4.9 %). An impact caused by main patient and donor characteristics, established risk factors for SOS, and conditioning regimen could be excluded in multivariate analyses. CONCLUSIONS: HPSE polymorphisms turned out to be significant independent risk factors (P = 0.030) for development of SOS and should be evaluated in further trials.
PURPOSE:Sinusoidal obstruction syndrome (SOS) is a life-threatening early complication after hematopoietic stem cell transplantation (HSCT), and until now, examinations about the influence of genetic risk factors are extremely rare. The purpose of this study was to identify an association between heparanase (HPSE) single nucleotide polymorphisms (SNPs) and SOS in children undergoing allogeneic HSCT. METHODS: We retrospectively analyzed the distribution of the both HPSE SNPs rs4693608 and rs4364254 and the occurrence of SOS after allogeneic HSCT in 160 children with malignant and non-malignant diseases. RESULTS:Patients with HPSE genotypes GG or AG of rs4693608 (G>A) had a significantly reduced incidence of SOS on day 100 after HSCT compared to patients with genotype AA (4.7 vs. 14.3 %, P = 0.038). In addition, incidence of SOS in patients with genotype CC or CT of rs4364254 (C>T) was significantly decreased in comparison with patients with genotype TT (2.3 vs. 14.7 %, P = 0.004). Interestingly, no patient with genotype CC developed SOS. Because both SNPs co-occur in vivo, we generated subsets: AA-TT, GG-CC, and a group with remaining SNP combinations. We found significant differences between all three patient groups (P = 0.035). Patients with AA-TT showed the highest incidence of SOS (16.7 %), while SOS did not appear in patients with GG-CC (0 %) and residual combinations were numerically in-between (4.9 %). An impact caused by main patient and donor characteristics, established risk factors for SOS, and conditioning regimen could be excluded in multivariate analyses. CONCLUSIONS:HPSE polymorphisms turned out to be significant independent risk factors (P = 0.030) for development of SOS and should be evaluated in further trials.
Authors: R Chopra; J D Eaton; A Grassi; M Potter; B Shaw; C Salat; P Neumeister; G Finazzi; M Iacobelli; K Bowyer; H G Prentice; T Barbui Journal: Br J Haematol Date: 2000-12 Impact factor: 6.998
Authors: June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steve M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis J Giles Journal: Leuk Res Date: 2006-09-07 Impact factor: 3.156
Authors: Rudolf Pihusch; Christoph Salat; Edwin Schmidt; Peter Göhring; Markus Pihusch; Erhard Hiller; Ernst Holler; Hans-Jochem Kolb Journal: Transplantation Date: 2002-11-15 Impact factor: 4.939
Authors: Simone Cunha Maradei; Angelo Maiolino; Alexandre Mello de Azevedo; Marta Colares; Luis Fernando Bouzas; Marcio Nucci Journal: Blood Date: 2009-04-28 Impact factor: 22.113
Authors: Constantine S Mitsiades; Cecile Rouleau; Cinara Echart; Krishna Menon; Beverly Teicher; Maria Distaso; Antonio Palumbo; Mario Boccadoro; Kenneth C Anderson; Massimo Iacobelli; Paul G Richardson Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531
Authors: Fiona L Dignan; Robert F Wynn; Nedim Hadzic; John Karani; Alberto Quaglia; Antonio Pagliuca; Paul Veys; Michael N Potter Journal: Br J Haematol Date: 2013-09-17 Impact factor: 6.998
Authors: Paul G Richardson; Stephan A Grupp; Antonio Pagliuca; Amrita Krishnan; Vincent T Ho; Selim Corbacioglu Journal: Int J Hematol Oncol Date: 2017-08-11
Authors: Nicolas Waespe; Sven Strebel; Simona Jurkovic Mlakar; Maja Krajinovic; Claudia Elisabeth Kuehni; Tiago Nava; Marc Ansari Journal: J Pers Med Date: 2021-04-26
Authors: M Mohty; F Malard; M Abecassis; E Aerts; A S Alaskar; M Aljurf; M Arat; P Bader; F Baron; A Bazarbachi; D Blaise; F Ciceri; S Corbacioglu; J-H Dalle; R F Duarte; T Fukuda; A Huynh; T Masszi; M Michallet; A Nagler; M NiChonghaile; T Pagluica; C Peters; F B Petersen; P G Richardson; T Ruutu; B N Savani; E Wallhult; I Yakoub-Agha; E Carreras Journal: Bone Marrow Transplant Date: 2015-03-23 Impact factor: 5.483
Authors: S Corbacioglu; E Carreras; M Ansari; A Balduzzi; S Cesaro; J-H Dalle; F Dignan; B Gibson; T Guengoer; B Gruhn; A Lankester; F Locatelli; A Pagliuca; C Peters; P G Richardson; A S Schulz; P Sedlacek; J Stein; K-W Sykora; J Toporski; E Trigoso; K Vetteranta; J Wachowiak; E Wallhult; R Wynn; I Yaniv; A Yesilipek; M Mohty; P Bader Journal: Bone Marrow Transplant Date: 2017-07-31 Impact factor: 5.483